eli lilly tirzepatide trial on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 Tirzepatide gets a big win

This might explain why some people dont experience immediate results from oral supplements alone

Teva Pharmaceutical Ltd

Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study

5 Resources for pharmacist authors who want to narrate their own audiobook Imagine this

Semaglutide, in the phase 3 STEP 1 trial, produced roughly 14.9% at the 2.4 mg dose over 68 weeks, versus about 2.4% for placebo a treatment difference of about 12.4 percentage points

Second, it argues against a pure placebo effect, because placebo responses tend to diminish more gradually